메뉴 건너뛰기




Volumn 31, Issue 2, 2008, Pages 141-149

Comparison of disability and quality of life measures in patients with long-term psychotic disorders and patients with multiple sclerosis: An application of the WHO Disability Assessment Schedule II and WHO Quality of Life-BREF

Author keywords

Disability; Health related quality of life; Multiple sclerosis; Psychotic disorders; WHO Disability Assessment Schedule II; WHO Quality of Life

Indexed keywords

HANDICAPPED PERSONS; MEDICAL PROBLEMS; PATIENT REHABILITATION; RISK ASSESSMENT;

EID: 43449120966     PISSN: 03425282     EISSN: None     Source Type: Journal    
DOI: 10.1097/MRR.0b013e32830150e6     Document Type: Article
Times cited : (30)

References (10)
  • 1
    • 4544352627 scopus 로고    scopus 로고
    • The assessment of patients with long-term psychotic disorders: Application of the WHO Disability Assessment Schedule II
    • Chopra PK, Couper J, Herrman H (2004). The assessment of patients with long-term psychotic disorders: application of the WHO Disability Assessment Schedule II. Aust N Z J Psychiatry 38:753-759.
    • (2004) Aust N Z J Psychiatry , vol.38 , pp. 753-759
    • Chopra, P.K.1    Couper, J.2    Herrman, H.3
  • 2
    • 0036012848 scopus 로고    scopus 로고
    • The Australian National Survey of Psychotic Disorders: Profile of psychosocial disability and its risk factors
    • Gureje O, Herrman H, Harvey C, Morgan V, Jablensky A (2002). The Australian National Survey of Psychotic Disorders: profile of psychosocial disability and its risk factors. Psychol Med 32:639-647.
    • (2002) Psychol Med , vol.32 , pp. 639-647
    • Gureje, O.1    Herrman, H.2    Harvey, C.3    Morgan, V.4    Jablensky, A.5
  • 3
    • 0031910303 scopus 로고    scopus 로고
    • Long-term outcome and rehabilitation
    • Herrman H (1998). Long-term outcome and rehabilitation. Curr Opin Psychiatry 11:175-182.
    • (1998) Curr Opin Psychiatry , vol.11 , pp. 175-182
    • Herrman, H.1
  • 4
    • 0035907398 scopus 로고    scopus 로고
    • Neurological disability and neurological rehabilitation
    • Macdonell RAL, Dewey HM (2001). Neurological disability and neurological rehabilitation. Med J Aust 174:653-658.
    • (2001) Med J Aust , vol.174 , pp. 653-658
    • Macdonell, R.A.L.1    Dewey, H.M.2
  • 5
    • 1542284175 scopus 로고    scopus 로고
    • Do general and multiple sclerosis quality of life instruments differ?
    • Moore F, Wolfson C, Alexandrov L, Lapierre Y (2004). Do general and multiple sclerosis quality of life instruments differ? Can J Neurol Sci 31:64-71.
    • (2004) Can J Neurol Sci , vol.31 , pp. 64-71
    • Moore, F.1    Wolfson, C.2    Alexandrov, L.3    Lapierre, Y.4
  • 7
    • 0038660066 scopus 로고    scopus 로고
    • Patient and community preferences for treatments and health states in multiple sclerosis
    • Prosser LA, Kuntz KM, Bar-Or A, Weinstein MC (2003). Patient and community preferences for treatments and health states in multiple sclerosis. Mult Scler 9:311-319.
    • (2003) Mult Scler , vol.9 , pp. 311-319
    • Prosser, L.A.1    Kuntz, K.M.2    Bar-Or, A.3    Weinstein, M.C.4
  • 8
    • 0026471906 scopus 로고
    • Quality of life in multiple sclerosis: Comparison with inflammatory bowel disease and rheumatoid arthritis
    • Rudick RA, Miller D, Clough J, Gragg LA, Farmer R (1992). Quality of life in multiple sclerosis: comparison with inflammatory bowel disease and rheumatoid arthritis. Arch Neurol 49:1237-1242.
    • (1992) Arch Neurol , vol.49 , pp. 1237-1242
    • Rudick, R.A.1    Miller, D.2    Clough, J.3    Gragg, L.A.4    Farmer, R.5
  • 9
    • 0031899459 scopus 로고    scopus 로고
    • Multiple sclerosis: Assessment of disability and disability scales
    • Thompson AJ, Hobart JC (1998). Multiple sclerosis: assessment of disability and disability scales. J Neurol 245:189-196.
    • (1998) J Neurol , vol.245 , pp. 189-196
    • Thompson, A.J.1    Hobart, J.C.2
  • 10
    • 43449126325 scopus 로고    scopus 로고
    • WHO 1999, WHO-DAS II, Version 3.1a Phase Two Field Trials June 1999. Geneva: World Health Organisation
    • WHO (1999). WHO-DAS II, Version 3.1a Phase Two Field Trials June 1999. Geneva: World Health Organisation.


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.